Drug
TAK-875 clinical trials
Also written TAK-875 and Fasiglifam.
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2012 (7)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TAK-875 is read from its arms, and is right about nine times in ten.
Testing it · 18
- Fasiglifam 25 mg BID vs 50 mg QDTerminatedPhase 2TakedaNCT01982253Written as Fasiglifam
- Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 DiabetesTerminatedPhase 3TakedaNCT01549964Written as Fasiglifam (TAK-875)
- Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesTerminatedPhase 3TakedaNCT01481116Written as TAK-875
- TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 DiabetesTerminatedPhase 3TakedaNCT01829464Written as TAK-875
- Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 DiabetesTerminatedPhase 3TakedaNCT01829477Written as TAK-875
- Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes MellitusCompletedPhase 2TakedaNCT01007097Written as TAK-875
- Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 DiabetesCompletedPhase 3TakedaNCT01456195Written as Fasiglifam
- Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusCompletedPhase 2TakedaNCT01414920Written as TAK-875
- Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 DiabetesTerminatedPhase 3TakedaNCT01647542Written as TAK-875
- Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseTerminatedPhase 3TakedaNCT01609582Written as TAK-875
- Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesTerminatedPhase 3TakedaNCT01834274Written as Fasiglifam (TAK-875)
- Long-term Study of TAK-875CompletedPhase 3TakedaNCT01433406Written as TAK-875
- Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on HemodialysisWithdrawnPhase 3TakedaNCT02015780Written as Fasiglifam
- Double Blind Comparative Study of TAK-875CompletedPhase 3TakedaNCT01585792Written as TAK-875
- Open-label Study of TAK-875CompletedPhase 3TakedaNCT01433419Written as TAK-875
- Double-blind Comparative Study of TAK-875CompletedPhase 3TakedaNCT01433393Written as TAK-875
- TAK-875 Glimepiride Drug-Interaction StudyCompletedPhase 1TakedaNCT01496443Written as TAK-875 and Glimepiride
- Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 DiabetesCompletedPhase 1TakedaNCT00949091Written as TAK-875
Codes
What other systems call TAK-875 · ClinicalTrials.gg INT005798
Also registered as fasiglifam (UNII GLP1W4JXAH) and fasiglifam hemihydrate (UNII 8LDT91CH8A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.